Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2601 |
Vidofludimus
SC12267,4sc-101 |
Dehydrogenase; DNA/RNA Synthesis; Interleukin | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Immunology/Inflammation; Metabolism |
Vidofludimus (SC12267) 是一种新型的二氢乳清酸脱氢酶 (DHODH) 小分子抑制剂,可在不影响淋巴细胞增殖的条件下抑制IL-17的分泌。 | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, w... | |||
T70899 |
Vidofludimus hemicalcium
4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium |
||
Vidofludimus (4sc-101 ; SC12267) hemicalcium 是一种口服有效的二氢乳清酸脱氢酶 (DHODH) 的抑制剂,也是法尼醇 X 受体 (FXR) 调节剂。Vidofludimus hemicalcium 作为一种免疫调节剂,可用于研究自身免疫性疾病,如炎症性肠病 (IBD)。Vidofludimus hemicalcium 还可通过靶向FXR 用于脂肪肝的研究。 |